Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Providing Genomic Testing for Pharmatech's Cancer Registry

NEW YORK (GenomeWeb) – Paradigm today announced it has initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.

Non-profit diagnostics shop Paradigm offers a next-generation sequencing-based cancer test called PCDx that sequences both DNA and RNA. It will provide the test for patients that are enrolled in Pharmatech's AccessPPM, a cancer registry that collects electronic medical record data and genomic information to match cancer patients with targeted clinical trials.

"We believe AccessPPM will change the way today's oncology patient accesses clinical trials and will help pharmaceutical companies identify patients that are truly interested in research," Pharmatech CEO Rob Bohacs said in a statement.

Financial and other terms of the deal were not disclosed.